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Summary  Severe  malaria  kills  more  than  a  half  million  people  each  year.  Based  on
high-quality  evidence  of  the  efﬁcacy  superiority  of  artesunate  over  quinine  in  adults
and  children  with  severe  malaria,  the  World  Health  Organization  guidelines  have
been  revised.  The  WHO  currently  recommends  injectable  artesunate  as  the  ﬁrst-line
treatment  for  severe  malaria.  Since  this  revision  in  April  2011,  only  a  small  number
of  countries  affected  by  malaria  have  adopted  and  implemented  the  new  policy.  If
this  policy  is  implemented,  an  additional  195,000  lives  would  be  saved  each  year  in
Africa.  Thus,  there  is  an  urgent  need  to  speed  up  access  to  injectable  artesunate
in  malaria-endemic  countries.  This  review  presents  a  background  for  recommen-
ding  artesunate  as  the  ﬁrst-line  treatment  of  severe  malaria  in  children  and
adults,  and  interventions  that  are  recommended  to  accelerate  access  to  injectable
artesunate.
©  2014  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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alaria  is a  preventable  and  treatable  mosquito-
orne disease  and  a  major  contributor  to  morbidity
nd  mortality  globally.  In  2012,  there  were  an  esti-
ated 207  million  cases  of  malaria  globally  and
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876-0341/© 2014 King Saud Bin Abdulaziz University for Health Sciepproximately  627,000  deaths.  African  children  are
ostly affected.  Approximately  90%  of  all  malaria-
elated  deaths  occur  in  Africa,  with  77%  being
hildren below  ﬁve  years  [1].
Anti-malaria interventions  include  long-lasting
nsecticidal nets,  indoor  residual  spraying,  inter-
ittent  preventive  treatment,  improved  diagnosis
sing  rapid  diagnostic  tests  and  adequate  treat-
ent of  uncomplicated  cases  using  artemisinin
ombination therapy  as  ﬁrst-line  therapy  [2].  In
esponse  to  calls  for  widespread  control  and
nces. Published by Elsevier Ltd. All rights reserved.
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elimination  of  malaria  and  the  challenge  of  meet-
ing the  Millennium  Development  Goals  4  and  6,
there has  been  a  rapid  scale-up  of  these  interven-
tions [2].  Reducing  the  mortality  due  to  malaria
also requires  universal  access  to  appropriate  treat-
ment for  severe  cases.  It  is  estimated  that  8
million cases  of  uncomplicated  malaria  progress
to severe  malaria  annually  [3].  Many  affected
children die  before  admission  to  a  hospital  or
clinic,  but  for  those  who  are  admitted  with  severe
malaria and  receive  parenteral  antimalarial  treat-
ment, approximately  one  in  six  will  die  [4]. The
policy for  ﬁrst-line  treatment  of  severe  malaria
is therefore  a  critical  factor  in  reducing  malaria
mortality.
Following the  emergence  of  chloroquine-related
resistance  in  the  1970s  in  South  East  Asia  and  Africa,
until recently,  quinine  has  remained  the  standard
treatment of  severe  malaria  in  Sub-Saharan  Africa.
In 2011,  based  on  recent  high-quality  evidence  of
the efﬁcacy  superiority  of  artesunate  over  qui-
nine in  adults  and  children  with  severe  malaria,
the World  Health  Organization  (WHO)  guidelines
were revised  to  recommend  injectable  artesunate
as the  ﬁrst-line  treatment  for  severe  malaria  in  both
adults and  children  [5].
Since the  revision  of  WHO  guidelines  for
the treatment  of  severe  malaria,  some  African
countries have  revised  their  severe  malaria  treat-
ment guidelines  to  reﬂect  the  WHO  recommenda-
tion. However,  to  date,  only  few  countries  affected
by malaria  have  adopted  and  implemented  the  new
policy [1].  Assuming  that  treating  severe  malaria
with artesunate  instead  of  quinine  reduces  the  risk
of death  by  39%  in  adults  and  24%  in  children  [6],  it
is estimated  that  the  use  of  injectable  artesunate
as a  ﬁrst-line  drug  throughout  Africa  theoretically
would save  up  to  an  additional  195,000  lives  among
the estimated  8  million  annual  cases  of  severe
malaria [3].  Therefore,  speeding  up  access  to
injectable  artesunate  in  malaria-endemic  countries
is an  emergency.  This  review  presents  evidence
on the  efﬁcacy  and  safety  superiority  of  arte-
sunate over  quinine  in  adults  and  children  with
severe malaria  and  interventions  that  have  been
recommended  to  accelerate  access  to  injectable
artesunate.
Superior efﬁcacy of artesunate over
quinineParenteral  quinine  has  remained  the  standard
treatment of  severe  malaria  for  nearly  three
decades. The  primacy  of  parenteral  quinine  in  the
t
a
r
tJ.J.N.  Noubiap
reatment  of  severe  malaria  has  been  challenged
y the  introduction  of  artemisinin  derivatives  (arte-
unate, artemether  and  artemotil).  This  primacy
as established  before  modern  clinical  trial  meth-
ds were  developed.
A recent  Cochrane  meta-analysis  including  8
rials compared  the  efﬁcacy  of  quinine  (com-
arator) with  artesunate  (intervention)  for  severe
alaria  in  endemic  settings  [6]. This  meta-analysis
ncluded the  two  largest  trials  in  children  and
dults, the  South  East  Asian  Quinine  Artesunate
alaria Trial  (SEAQUAMAT)  and  the  African  Quinine
ersus  Artesunate  Malaria  Trial  (AQUAMAT).  The  pri-
ary outcome  was  all-cause  death.  The  quality  of
he evidence  was  assessed  using  the  Grading  of
ecommendations,  Assessment,  Development  and
valuation (GRADE)  approach  that  classiﬁes  the
ggregate  level  of  quality  of  evidence  into  4  cat-
gories:  high,  moderate,  low  or  very  low  [7].
Parenteral artesunate  signiﬁcantly  reduced  the
isk of  death  from  severe  malaria  compared  with
ntravenous  quinine  both  in  adults  (5  trials,  1664
articipants;  total  events:  124  (artesunate),  198
quinine); RR  0.61,  95%  CI  0.5—0.75;  high  qual-
ty evidence)  and  in  children  (4  trials,  5765
articipants; total  events:  240  (artesunate),  315
quinine); RR  0.76,  95%  CI  0.65—0.90;  high-quality
vidence). These  results  indicate  that  treating
evere malaria  with  artesunate  instead  of  quinine
educes  the  risk  of  death  by  39%  in  adults  (95%
I 25—50)  and  24%  in  children  (95%  CI  10—35).
rtesunate  reduced  the  frequency  of  hypoglycemia
pisodes in  children  (4  trials,  5765  participants;
otal events:  54  (artesunate),  87  (quinine);  RR
.62, 95%  CI  0.45—0.87;  high  quality  evidence)
nd in  adults  (2  trials,  1372  participants;  total
vents:  12  (artesunate),  32  (quinine);  RR  0.36,  95%
I 0.19—0.68;  high  quality  evidence).  This  corre-
ponds to  a 45%  (95%  CI  26—59%)  reduction  of
ypoglycemia episodes  during  treatment  with  arte-
unate. No  difference  has  been  demonstrated  for
he risk  of  serious  neurological  sequelae  in  chil-
ren at  day  28  (1  trial,  4857  participants;  total
vents: 34  (artesunate),  27  (quinine);  RR  1.23,  95%
I 0.74—2.03;  moderate  quality  evidence),  though
rtesunate  was  associated  with  an  increased  risk
f neurological  sequelae  at  the  time  of  discharge
3 trial,  5163  participants;  total  events:  101  (arte-
unate),  72  (quinine);  RR  1.36,  95%  CI  1.01—1.83;
oderate quality  evidence)  [6]. As  clinical  seque-
ae are  less  common  than  death,  the  data  suggest
n overall  beneﬁt  from  artesunate  therapy  if  mor-
ality and  sequelae  are  considered  jointly  [8].  In
dults, the  data  also  suggest  no  difference  in  the
isk of  neurological  sequelae  at discharge  between
he two  treatments  (1  trial,  1259  participants;  total
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vents:  6  (artesunate),  2  (quinine);  RR  2.97,  95%  CI
.6—14.64; moderate  quality  evidence)  [6].
afety, toxicity and ease of
dministration of artesunate compared
ith  quinine
uinine  has  a  narrow  therapeutic  ratio,  with
requent side-effects  (cinchonism)  at  therapeutic
oses [4,9].  These  usually  mild  and  reversible  symp-
oms consist  of  tinnitus,  deafness,  dizziness  and
omiting  and  may  affect  adherence  [9].  Toxic  lev-
ls of  quinine  can  occur  following  rapid  intravenous
dministration  and  can  result  in  heart  rhythm  dis-
urbances,  blindness,  coma,  and  even  death.  Due
o the  risk  of  cardiotoxicity,  each  dose  of  par-
nteral quinine  must  be  administered  as  a  slow,
ate-controlled  infusion  (usually  diluted  in  5%  dex-
rose and  infused  over  4  h),  accompanied  by  cardiac
onitoring  if  possible.  The  infusion  rate  should  not
xceed 5 mg  salt/kg  body  weight  per  hour  [5]. A
tudy examining  malaria  deaths  reported  that  one
n four  patients  had  received  incorrect  dosing  [10].
urthermore,  quinine  can  induce  potentially  serious
yperinsulinemic  hypoglycemia,  which  is  a partic-
lar problem  in  patient  management,  especially  in
regnant women  [9]. Intramuscular  administration
f quinine  is  painful  and  can  cause  sterile  abscesses
nd predispose  patients  to  lethal  tetanus  [11].
On the  contrary,  injectable  artesunate  is  sim-
ler to  administer,  intravenously  or  intramuscularly,
ith the  treatment  delivered  in  5 min  [12].
owever, treatment  with  artesunate  presents  a
ose-dependent  risk  of  transient  neutropenia.
ethell et  al.  [13]  studied  the  occurrence  of
eutropenia after  7-day  courses  of  artesunate
onotherapy  in  Cambodian  patients  with  acute
lasmodium  falciparum  malaria.  Patients  with
ncomplicated  malaria  were  allocated  1  of  3
ral artesunate  monotherapy  regimens  (2,  4,  or
 mg/kg/day  for  7  days),  and  a  complete  blood
ount was  performed  on  days  0,  3,  6,  and  14.
ecipients of  the  6  mg/kg/day  dosage  had  signif-
cantly  lower  geometric  mean  absolute  neutrophil
ounts than  did  recipients  of  the  2  and  4 mg/kg/day
osages at  6  and  14  days  (P  <  0.001  for  each).
evere neutropenia  (<1.0  ×  103/L)  was  observed
n 19%  of  patients  who  received  the  6 mg/kg/day
osage. This  study  suggests  that  giving  artesunate
p to  6  mg/kg/day  presents  a  risk  of  neutrope-
ia [13].  Nevertheless,  the  4  mg/kg/day  dose  given
rally for  7  days  is safe,  and  this  corresponds
pproximately  to  the  2.4  mg/kg  of  parenteral  arte-
unate, administered  twice  on  the  day  of  admission,
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ollowed  by  2.4  mg/kg  once  daily  [14]. This  pro-
ocol, which  achieves  maximal  parasite  clearance
ates against  sensitive  parasites  [14], was  evaluated
n the  AQUAMAT  and  SEAQUAMAT  trials  and  is  now
ecommended  by  the  WHO  [5].
ecommendations on injectable
rtesunate-based treatment of severe
alaria
he  WHO  recommends  that  artesunate,  which  is
he drug  of  choice  for  the  treatment  of severe
alaria, should  be  administered  parenterally  for  a
inimum of  24  h and  replaced  by  oral  medication
s soon  as  it  can  be  tolerated.  The  recommended
reatment  is  artesunate  at  2.4  mg/kg  body  weight
dministered  intravenously  or  intramuscularly  at
dmission (time  =  0),  then  12  h  and  24  h,  and  then
nce a  day  from  day  2.  All  cases  of  severe  malaria
hould be  treated  with  a full  course  of  a locally
ffective artemisinin-based  combination  medica-
ion once  the  patient  is  able  to  take  oral  medication
nd after  at least  24  h  of  parenteral  therapy  has
een completed  [5].
There  are  some  concerns  about  the  WHO-
ecommended  dosing  regimen  of  parenteral  arte-
unate in  small  children.  It  has  been  demonstrated
hat in  young  children  with  severe  disease,  the
harmacokinetic  properties  of  antimalarials  may
iffer from  those  reported  in  adults  [15—17].
n a  recent  population  pharmacokinetic  study  of
ntramuscular  artesunate  in  African  children  with
evere malaria,  Hendriksen  et  al.  suggested  that
mall children  treated  with  intramuscular  arte-
unate  are  under-dosed  compared  with  older  ones
18]. They  found  that  body  weight  signiﬁcantly
ffected elimination  clearance  and  apparent  vol-
me of  distribution,  resulting  in  lower  exposure
evels of  artesunate  and  its  active  metabolite,
ihydroartemisinin.  Therefore,  they  proposed  an
dapted artesunate  dosing  regimen  for  small  chil-
ren, including  a practical  dosing  table  per  weight
and (Table  1)  [18].
ost-effectiveness of injectable
rtesunate
ne  study  explored  the  cost  effectiveness  of  arte-
unate  for  the  treatment  of  severe  malaria  in
hildren and  its  potential  impact  on  hospital  budg-
ts by  assessing  the  costs  of  inpatient  care  of
hildren with  severe  malaria  in  4  of  the  11  sites
n the  AQUAMAT  study  [19]. The  cost  of  inpatient
410  J.J.N.  Noubiap
Table  1  Proposed  body  weight-adjusted  dosing  for  intramuscular  artesunate  [18].
Weight  (kg)  Dose  IM  (mg)  Prepared  solution  (ml)a Dose  IM  (mg/kg)
6—7  20  2  2.86—3.33
8—9  25  2.5b 2.78—3.13
10—11  30  3b  2.73—3.00
12—13  35  3.5b 2.69—2.92
14—16  40  2  2.50—2.86
17—20  50  2.5  2.50—2.94
21—25 60  3  2.40—2.86
IM, intramuscular.
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ta For children of body weights <14 kg, dilute to 10 mg/ml; f
b Divide the dose equally and administer into both thighs.
care  included  the  cost  of  hospital  accommodation,
drugs, laboratory  tests  and  intravenous  ﬂuids  pro-
vided to  2300  children  from  admission  to  discharge.
The costs  associated  with  nursing  time  and  costs
of consumables  such  as  syringes,  needles,  cannulas
and  infusion  sets  were  excluded.
This analysis  indicated  that  the  cost  of  avert-
ing malaria-related  deaths  in  sub-Saharan  Africa  by
switching from  quinine  to  artesunate  was  extremely
low, with  a  mean  value  of  US$  123  per  death
averted, and  an  incremental  cost  per  disability-
adjusted life  year  (DALY)  prevented  of  US$  3.8.
These  costs  were  at  those  levels  despite  the  mean
cost of  treating  severe  malaria  in  the  artesunate
arm being  US$  66.5  (95%  CI  63.7—69.2)  compared
with US$  63.5  (95%  CI  61.7—65.2)  in  the  quinine
arm. The  authors  also  considered  that  both  the
labor and  consumables  costs  that  were  not  included
in their  analysis  are  likely  to  be  marginally  higher
with quinine  than  artesunate  because  quinine  is
administered  3  times  per  day,  and,  as  an  infu-
sion, the  drug  requires  extra  consumables  and
careful  monitoring.  The  inclusion  of  costs  related
to those  extra  requirements  would  therefore  fur-
ther enhance  the  cost-effectiveness  of  artesunate.
Moreover, reducing  nursing  time  can  improve  the
care for  other  patients  and  in  the  long  run  could
have a  potential  impact  on  hospital  budgets.  The
study authors  conclude  that  artesunate  is  thus  a
highly affordable  and  cost-effective  alternative  to
quinine for  treating  children  with  severe  malaria  in
sub-Saharan  Africa  [19].
Speeding up access to injectable
artesunateThere  are  many  challenges  related  to  the  adop-
tion and  implementation  of  injectable  artesunate
in malaria-affected  countries.  As  presented  by  the
Injectable  Artesunate  Stakeholders’  Meeting  [3],
e
d
t
dildren with body weights ≥14 mg, dilute to 20 mg/ml.
ecommendations  that  would  help  to  speed  up
ccess  to  injectable  artesunate  can  be  summarized
sing four  axes:
ncouraging policy
t  is  critical  for  health  ministries  of  malaria-
ndemic countries  to  adopt  injectable  artesunate
s the  ﬁrst-line  treatment  for  severe  malaria  in
heir national  treatment  guidelines,  as  recom-
ended by  the  WHO.  To  implement  the  treatment
ecommendation  by  distributing  and  using  the  drug
ll over  the  country,  the  drug  should  ﬁrst  be  regis-
ered and  included  on  the  national  list  of  approved
rugs [3].  For  example,  it has  been  reported  in
ay 2013  that  artesunate  was  not  registered  in
outh  Africa,  despite  requests  to  the  manufacturer
rom South  African  authorities  since  2007,  and  the
arenteral Artesunate  Access  Program,  which  was
reated in  2010  to  promote  widespread  availabil-
ty of  artesunate,  has  remained  unfunded  [20].
he introduction  of  injectable  artesunate  by  gov-
rnments  requires  effective  communications  on
ts effectiveness  and  beneﬁts  in  the  context  of
ach country,  a clear  deﬁnition  of  the  projected
ational funding  requirements  and  available  ﬁnan-
ial sources  [3].
Malaria  remains  inextricably  linked  with  poverty.
he highest  malaria  mortality  rates  are  observed  in
ountries that  have  the  highest  rates  of  extreme
overty (proportion  of  population  living  on  less  than
S$ 1.25  per  day)  [1]. An  estimated  US$  5.1  bil-
ion is needed  every  year  between  2011  and  2020
o achieve  universal  access  to  malaria  prevention,
iagnostic testing,  and  treatment  around  the  world.
n 2011,  only  US$  2.3  billion  was  available,  less
han half  of  what  is  needed,  and  national  gov-
rnment funding  represented  only  21.4%  of  total
isbursements  for  malaria  programs  [1]. To  scale-up
he access  to  injectable  artesunate,  funding  from
iverse international  global  health  initiatives  will
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tirst-line  treatment  of  severe  malaria  in  children  a
e  needed  to  support  resource-limited  countries.
or instance,  UNITAID  recently  awarded  a  grant  to
edicines for  Malaria  Venture  (MMV)  to  implement
ome market  interventions  that  will  reduce  the  bur-
en of  severe  malaria.  These  interventions  include
he purchase  and  supply  of  injectable  artesunate
or six  beneﬁciary  countries  from  2013—2016:
ameroon,  Uganda,  Kenya,  Malawi,  Ethiopia  and
igeria [21].  In  addition,  governments  should  be
rovided cost  tools  to  calculate  the  projected  fund-
ng requirements.  For  this  purpose,  MMV  and  the
ahidol-Oxford  Tropical  Medicine  Research  Unit
ave developed  an  easy-to-use  calculator  that
llows  governments  to  estimate  the  injectable
rtesunate funding  requirements  and  the  number
nd costs  of  death  averted  [12].
Furthermore,  there  is a  need  to  widely  and
learly inform  all  the  actors  on  the  primacy  of
njectable artesunate,  especially  the  key  opinion
eaders  who  can  inﬂuence  the  policy  adoption  by
he health  ministries  and  health  care  providers  [3].
upporting implementation
o  minimize  the  lag  between  the  adoption  of
njectable artesunate  by  a  health  ministry  and  its
arge-scale  use,  there  is  a  need  to  deﬁne  clear
ransition plans.  These  plans  should  cover  regula-
ory approval,  development  of  training  materials
nd communication  tools,  and  resource  mobiliza-
ion. The  effectiveness  and  beneﬁts  of  injectable
rtesunate should  be  promoted  among  clinicians
hrough conferences,  meetings  and  other  effec-
ive communication  canals,  and  there  should  be  a
ontinuous  sharing  of  knowledge,  experience  and
essons  learned.  It  is  important  to  raise  public
wareness of  the  new  drug  and  policy,  as  well  as  the
ecessity  of  identifying  early  and  promptly  cases
f severe  malaria  for  referral.  Strategies  should
ffectively involve  the  private  sector  to  assure  har-
onized  implementation  with  the  public  sector  [3].
n collaboration  with  drug  manufacturers,  simple,
tandardized  and  easy-to-use  forms  of  artesunate
hould be  developed  and  made  available.  An  esti-
ated  48—50  million  vials  are  needed  globally  each
ear. In  2011,  only  2  million  vials  were  provided
y the  current  sole  manufacturer  who  has  been
ranted WHO  prequaliﬁcation  for  injectable  arte-
unate [21].  Other  manufacturers  are  needed  to
chieve a  sufﬁcient  and  sustained  supply  of  the
roduct.raining
t  is  important  to  familiarize  clinicians  with
he practical  aspects  of  the  use  of  injectable
i
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gdults  411
rtesunate  and  update  their  knowledge  on  malaria
iagnosis  and  case-management.  The  best  training
pproaches  should  be  developed  to  boost  atten-
ance  at  training  sessions.  These  may  include
exible, short,  concise  and  practical  courses  with
dequate  tools  and  remuneration  for  attendance.
osters representing  treatment  guidelines  should
e made  available  everywhere  needed  in  health
acilities. For  this  purpose,  MMV  has  produced  a
ery useful  set  of  training  support  materials  [22].
edical and  nursing  schools  should  include  new
reatment guidelines  in  curricula  [3].
The use  of  wireless  communication  technolo-
ies would  contribute  to  the  scaling-up  the  use
f injectable  artesunate.  A  trial  in  Kenya  demon-
trated that  simple  text-message  reminders  sent
egularly  to  health  workers’  personal  mobile  phones
ubstantially  improved  the  management  of  pedi-
tric outpatients  in  accordance  with  national
alaria guidelines  [23]. A  further  analysis  demon-
trated  that  this  intervention  is  effective  and
nexpensive [24].  Mobile  phone  text-messages
hould be  used  to  enhance  health  care  providers’
dherence to  the  new  malaria  treatment  guide-
ines.
onitoring
here  is  a  need  to  monitor  the  implementation  of
he new  treatment  policy  as  to  detect  impediments
o overcome.  Changes  of  fatality  rates  in  severe
alaria can  be  used  to  monitor  the  programmatic
ffectiveness  of  deploying  injectable  artesunate
3]. However,  as  reported  by  the  WHO,  malaria
urveillance systems  remain  very  weak,  detecting
nly approximately  10%  of  the  estimated  global
urden  of  cases  [1]. Therefore,  there  should  be
fforts to  improve  malaria  monitoring  and  reporting
ystems.
onclusions
njectable  artesunate  is  the  WHO-recommended
reatment  for  severe  malaria  in  children  and  adults.
he drug  is anticipated  to  signiﬁcantly  reduce  the
urrent mortality  due  to  malaria.  Unfortunately,
o date,  not  all  malaria-endemic  countries  have
dopted  and  implemented  the  WHO  recommen-
ations. There  is  an  urgent  need  to  speed  up
he adoption  and  implementation  of  this  new  pol-
cy. Recommendations  for  effective  interventions
ave been  proposed.  Financial  support  to  gov-
rnments is  a  key  component  of  achieving  this
oal.
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